The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

It sounds like the tail end of a pharmaceutical commercial: "A month's supply of insulin could cost as little as $35." But that's the deal New Mexico Attorney General Raúl Torrez is poised to maintain ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...

In settlements, two insulin manufacturers committed to selling insulin to New Mexicans for $35 or less per month.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...